Taverner Alistair, Almansour Khaled, Gridley Kate, Marques Ana Rita Lima, MacKay Julia, Eggleston Ian M, Mrsny Randall J
Department of Life Sciences, Centre for Therapeutic Innovation, University of Bath, Bath BA2 7AY, UK.
Department of Pharmaceutics, College of Pharmacy, University of Hail, Ha'il 55473, Saudi Arabia.
J Control Release. 2023 Oct 27. doi: 10.1016/j.jconrel.2023.10.044.
The intestinal paracellular route of absorption is modulated via tight junction (TJ) structures located at the apical neck of polarized intestinal epithelial cells to restrict solute movement through the intercellular space between them. Tight junctions open or close in response to changes in the phosphorylation status of light chain (MLC) at position Ser-19. This phosphorylation event is primarily controlled by MLC kinase (MLCK) and MLC phosphatase (MLCP), the latter being a holoenzyme that involves interaction between protein phosphatase 1 (PP1) and myosin targeting protein 1 (MYPT1). An entirely D-amino acid Permeant Inhibitor of Phosphatase (PIP) peptide sequence designed to disrupt PP1-MYPT1 interactions at the cytoplasmic surface of TJs, PIP250 (rrfkvktkkrk) localized at intracellular TJ structures, altered expression levels of specific TJ proteins, increased cellular phosphorylated MLC (pMLC) levels, binding to PP1, decreased epithelial barrier function, and significantly increased systemic uptake of the poorly absorbed antibiotic gentamicin in vivo. A series of PIP250 peptide analogues showed that positions phe3 and val5 were critical to its functional properties, with some providing opportunities to tune the dynamic actions of its TJ modulation properties. These data confirm the activity of PIP250 as a rationally designed oral permeation enhancer and validated key amino acids involved in its interaction with PP1 that define its overall actions; the magnitude and duration of these enhancing properties were associated with the MYPT1-mimetic properties of the PIP250 peptide analogues described.
肠道旁细胞吸收途径是通过位于极化肠上皮细胞顶端颈部的紧密连接(TJ)结构来调节的,以限制溶质在它们之间的细胞间隙中移动。紧密连接会根据丝氨酸-19位置的轻链(MLC)磷酸化状态的变化而打开或关闭。这种磷酸化事件主要由MLC激酶(MLCK)和MLC磷酸酶(MLCP)控制,后者是一种全酶,涉及蛋白磷酸酶1(PP1)和肌球蛋白靶向蛋白1(MYPT1)之间的相互作用。一种完全由D-氨基酸组成的磷酸酶渗透抑制剂(PIP)肽序列,设计用于破坏TJ细胞质表面的PP1-MYPT1相互作用,PIP250(rrfkvktkkrk)定位于细胞内TJ结构,改变了特定TJ蛋白的表达水平,增加了细胞磷酸化MLC(pMLC)水平,与PP1结合,降低了上皮屏障功能,并在体内显著增加了吸收不良的抗生素庆大霉素的全身摄取。一系列PIP250肽类似物表明,第phe3和val5位对其功能特性至关重要,其中一些提供了调节其TJ调节特性动态作用的机会。这些数据证实了PIP250作为一种合理设计的口服渗透增强剂的活性,并验证了参与其与PP1相互作用的关键氨基酸,这些氨基酸定义了其整体作用;这些增强特性的大小和持续时间与所描述的PIP250肽类似物模拟MYPT1的特性相关。